Catalent’s Partner, Biohaven, Announces It Has Initiated Expanded Access Program For Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets




Catalent’s partner, Biohaven, announces it has Initiated Expanded Access Program for Sublingual BHV-0223 ZYDIS® Orally Dissolving Tablets for Patients with Amyotrophic Lateral Sclerosis (ALS)

Learn more